Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.60 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.60 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 4/20 | 0.49 |
| ▸ | CCND1 | P24385 | 4/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.49 |
| ▸ | WEE1 | P30291 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | BRD4 | O60885 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5511668 | 0.89 | SRC (0.62) | FGFR1SRCPKMYT1PDGFRBSLC2A1 | |
| SCHEMBL5523958 | 0.87 | FGFR1 (0.58) | FGFR1SRCPKMYT1PDGFRBSLC2A1 | |
| SCHEMBL5523042 | 0.87 | SRC (0.74) | FGFR1SRCPKMYT1PDGFRBSLC2A1 | |
| SCHEMBL5520408 | 0.85 | FGFR1 (0.64) | FGFR1SRCPKMYT1PDGFRBSLC2A1 | |
| SCHEMBL5516295 | 0.80 | FGFR1 (0.56) | FGFR1SRCPKMYT1PDGFRBSLC2A1 | |
| SCHEMBL5534904 | 0.79 | CYP1A2 (0.74) | FGFR1SRCPKMYT1PDGFRBSLC2A1 | |
| SCHEMBL5633264 | 0.76 | CYP1A2 (0.47) | FGFR1SRCPKMYT1PDGFRBSLC2A1 | |
| SCHEMBL29508114 | 0.75 | SRC (1.00) | FGFR1SRCPKMYT1PDGFRBSLC2A1 | |
| SCHEMBL3458816 | 0.75 | SRC (1.00) | FGFR1SRCPKMYT1PDGFRBSLC2A1 | |
| SCHEMBL7694838 | 0.72 | CYP1A2 (0.73) | FGFR1SRCPDGFRBPDGFRAFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | claimed |
| EP-1409487-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-21 | — | — | EP | claimed |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | DENNY WILLIAM ALEXANDER (NZ) | 2003-07-10 | — | — | US | claimed |
| WO-2001019825-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-03-22 | — | — | WO | claimed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130286-A1 | Pteridinones as kinase inhibitors | CCNI, CCNK, CDK2 | FGFR1 91/4885SRC 1164/4885PKMYT1 777/4885 |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | CCNI, CCNK, CDK2 | FGFR1 50/4885SRC 579/4885PKMYT1 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.